about
Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infectionTrial watch: Dendritic cell-based anticancer therapyImmunity to HIV in Early LifeNeutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an FcγRIIa independent mechanism and do not diminish cytokines production.HIV-1 gp120 activates the STAT3/interleukin-6 axis in primary human monocyte-derived dendritic cellsBroadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes.HIV-1-induced impairment of dendritic cell cross talk with γδ T lymphocytes.Soluble CD40 ligand contributes to dendritic cell-mediated T-cell dysfunction in HIV-1 infection.Phenotypic and Functional Characterization of Monoclonal Antibodies with Specificity for Rhesus Macaque CD200, CD200R and MinclePharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential.Type I and Type II Interferon Coordinately Regulate Suppressive Dendritic Cell Fate and Function during Viral PersistenceImmunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial.HIV-1 Tat Protein Activates both the MyD88 and TRIF Pathways To Induce Tumor Necrosis Factor Alpha and Interleukin-10 in Human Monocytes.Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement.Future considerations for dendritic cell immunotherapy against chronic viral infections.Plasmacytoid Dendritic Cells: Neglected Regulators of the Immune Response to Staphylococcus aureus.Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.The Janus-faced nature of IDO1 in infectious diseases: challenges and therapeutic opportunities.HIV infection: focus on the innate immune cells.Dendritic Cell Response to HIV-1 Is Controlled by Differentiation Programs in the Cells and Strain-Specific Properties of the Virus.HIV-1 blocks the signaling adaptor MAVS to evade antiviral host defense after sensing of abortive HIV-1 RNA by the host helicase DDX3.HIV-1 Tat protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms.Mucosal Regulatory T Cells and T Helper 17 Cells in HIV-Associated Immune ActivationSAMHD1 degradation enhances active suppression of dendritic cell maturation by HIV-1.Vpx-containing dendritic cell vaccine induces CTLs and reactivates latent HIV-1 in vitro.Community-Acquired Pneumonia in HIV-Infected Individuals.Trial watch: Dendritic cell-based interventions for cancer therapy.Early SIV and HIV infection promotes the LILRB2/MHC-I inhibitory axis in cDCs.Embracing the complexity of HIV immunology.The Dynamic Interplay between HIV-1, SAMHD1, and the Innate Antiviral Response.Immune Interventions to Eliminate the HIV Reservoir.The Biology of Monocytes and Dendritic Cells: Contribution to HIV Pathogenesis.Advances in dendritic cell immunotherapies for HIV-1 infection.
P2860
Q27023322-FB3479FC-D5BE-4020-9708-71E728062F81Q27024047-9AA2C230-01F9-4E1B-B651-1820076A6244Q34033051-D8753B0C-6042-4753-BF45-27674CBFCA7EQ34055377-BBAF29E4-AF69-4EA4-8A62-7B1A109FB52EQ34261887-084D896C-39EE-4FEA-AC6F-B69DA31B3532Q34262089-DFDF6BBE-1956-46A0-8911-E93D7F814CD5Q35488947-171227B7-CEE0-418E-B90F-BF427074428AQ35772650-C153636A-6FDD-4D88-8DC0-1141B7344954Q35808060-DCE88EE7-93D0-424B-8A4C-ED99CF5BCDADQ35822086-13B0A5B9-5AF8-413E-B40B-A6339A2B9E66Q35903800-6D3DC499-ECD1-4737-ADD4-D5B21AE86CBFQ36576603-38C912D5-CF49-4B7C-BD85-85F69E6E6A1EQ37002574-E5367276-79E7-4623-9EDC-D4974E8F888BQ37642643-7985308E-420B-4458-90EC-1E57819F62E5Q38204769-001D5D3E-2A68-4EB0-8AF6-AD12EC746093Q38218117-14A2213C-C7BD-4D8D-8096-C3119B0FFD97Q38223279-F1CCEB60-C65D-4493-82C9-A84EF74D298BQ38675915-BD1E1216-9B98-4292-A917-10E2EA4E878BQ38945041-1C9460F3-C5E5-47B3-934B-93814BED5171Q40271149-477CFCEB-30DF-468C-BAC3-2F779A3238F5Q40395105-51541224-68F9-4EED-B7E7-5AD01A02142AQ40606349-B2B7968E-21A8-47F9-903C-2B79E25BC85FQ40625213-D0EF50A6-CA36-4860-B14B-E67DF91E8521Q41137160-99F31530-D621-43D5-85BB-646F8C412304Q41347747-990210A0-BDB6-4AE9-B01A-50F933595BEEQ42235608-2F94AE4C-FC9F-4DAD-8E31-4642A0DBE12DQ42867339-B00639DF-3448-41CB-9A8D-D157DFC15EE5Q44843573-7917B1B8-D1C2-417A-B636-4E6B999AB5FBQ46770038-E8AEA317-AD25-4423-97EA-1027C81CB0BAQ47118199-3E9A0D3F-E8C6-4EFA-A69B-0D265797EE4BQ47600062-4B363D25-3BA0-4FA0-80AD-2B94A935E8A8Q50131761-9F617AC4-30EE-44C0-ADBD-8C46AE8B1296Q51217825-AE471DAB-1A83-4C69-9A4F-206E5396D166
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dendritic cell dysregulation during HIV-1 infection.
@en
type
label
Dendritic cell dysregulation during HIV-1 infection.
@en
prefLabel
Dendritic cell dysregulation during HIV-1 infection.
@en
P2860
P356
P1476
Dendritic cell dysregulation during HIV-1 infection.
@en
P2093
Elizabeth Miller
Nina Bhardwaj
P2860
P304
P356
10.1111/IMR.12082
P577
2013-07-01T00:00:00Z